Could Tokenized Trading Change The Case For ImmunityBio Stock

• ImmunityBio founder Patrick Soon Shiong recently outlined plans for affiliated group Nant to build a blockchain enabled capital markets platform following an SEC decision to allow a five year exemption for trading tokenized U.S. stocks.
• This push into tokenized securities has fueled fresh retail interest because it ties ImmunityBio’s founder led ecosystem to an emerging trading infrastructure that could affect how investors access and hold IBRX over time.
• We will now explore how ImmunityBio’s investment narrative could be influenced by founder led plans for tokenized trading of U.S. shares.

Scan how ImmunityBio fits into the broader move toward tokenized and next generation trading by comparing it with a curated group of 19 cryptocurrency and blockchain stocks.

ImmunityBio Investment Narrative Recap

To own ImmunityBio, you need to believe its immunotherapy platform can move beyond a single bladder cancer use and turn a broad trial pipeline into commercial treatments. The near term focus still sits on ANKTIVA uptake and execution across 33 countries. The recent tokenization news does not directly change the medical or regulatory work that underpins that story.

The biggest swing factor remains whether new indications and geographies convert into meaningful product demand before funding pressure bites. ImmunityBio is still loss making, with negative shareholder equity and higher risk funding. Blockchain plans do not reduce clinical, reimbursement or competitive risks around ANKTIVA and the wider portfolio.

The announcement around Nant’s blockchain enabled capital markets build out is the clearest link to the recent news. Management is stitching together brokerage, transfer agent, exchange and blockchain settlement capabilities under one umbrella. That development could eventually influence how investors hold or trade ImmunityBio, especially if its shares are ever tokenized within that system.

For catalysts that matter most to ImmunityBio’s business, this sits in the background. Revenue growth, ANKTIVA adoption, progress in lymphopenia and recombinant BCG, and the push to move earnings from a loss of US$992.4m toward profitability are still what drive the story. Any trading infrastructure shift only matters if the underlying oncology and immunology franchise performs.

ImmunityBio’s narrative projects US$1.6b revenue and US$673.2m earnings by 2029. This assumes revenue grows at 125.9% per year and earnings increase by about US$1.53b from a current loss of US$854.5m to the 2029 consensus figure.

Uncover why ImmunityBio’s fair value indicates a 40% potential upside to its current price, a gap that may narrow as sentiment catches up.

Exploring Other Perspectives

One alternate view on ImmunityBio puts a spotlight on ANKTIVA concentration risk. If uptake or reimbursement across those 33 countries slows, the most cautious analysts, who were still pencilling in about US$1.7b revenue and US$719.9m earnings by 2029, might rethink their stance as the tokenization news feeds into fresh assumptions.

Explore 4 other ImmunityBio fair value estimates, including one that suggests it could be worth just $12.00!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider trusting your own analysis and judgment.

Looking For More Investment Ideas Beyond ImmunityBio?

If the ImmunityBio story has sharpened your thinking, it can be useful to compare it with other opportunities that share some of the qualities you care about, whether that is balance sheet strength, income potential, or a focus on resilient business models. The Simply Wall St Screener is built for that type of side by side work.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com